arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

HARROW, INC.

HROW
$40.53 ▲ +0.64 (+1.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
80 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

HARROW, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth -7.6%
Op. Margin -50.0%
ROIC -6.7%
FCF / Share $-0.25
Trailing P/E
Price / Book 52.6x
FCF Yield
Debt / Equity 10.45
info Valuation on last close. End-of-day price, Aug 7, 2026.

80-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.20M
↓ -7.6%
Net Income Profit after all expenses
$-27.60M
↓ -55.2%
Operating Margin Operating profit as % of sales
-50.0%
↓ -385.4% 59th
FCF / Share Free cash flow per share
$-0.25
↓ -156.0%
Long-Term Debt Long-term obligations
$300.00M
↑ +20.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
54
Returns
34
Financial Health
31
Cash Quality
2

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 29 years · 80 quarters